Austin Neuromuscular Center

Austin, Texas 78759

5 studies enrolling now · 29 studies all time

What they study most

ALS, Active Idiopathic Inflammatory Myopathy, Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation, Antiphospholipid Syndrome (APS), Antisynthetase Syndrome, Behçet's Syndrome (BS), Bullous Pemphigoid (BP), Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Cryptogenic Sensory Polyneuropathy, Dermatomyositis

Studies at this site

• Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Recruiting now
• Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) — Recruiting now
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) — Recruiting now
• Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) — Recruiting now
• Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis — Recruiting now
• A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. — Completed
• Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS — Stopped early
• A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) — Running, not enrolling
• A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy — Completed
• A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation — Running, not enrolling
• A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis — Completed
• Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis — Completed
• A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis — Completed
• Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis — Running, not enrolling
• Study of M5049 in DM and PM Participants (NEPTUNIA) — Stopped early
• MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) — Stopped early
• Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment — Stopped early
• Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment — Running, not enrolling
• A Study of TAK-079 in People With Generalized Myasthenia Gravis — Completed
• A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — Completed
• An Efficacy and Safety Study of Ravulizumab in ALS Participants — Stopped early
• Therapy in Amyotrophic Lateral Sclerosis (TAME) — Completed
• Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis — Completed
• Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy — Stopped early
• Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) — Completed
• Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS) — Stopped early
• A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps. — Stopped early
• Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations — Completed